CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Meridian Bioscience’s Illumigene group A Streptococcus and group B Streptococcus tests have been recategorized under CLIA as moderate complexity.
The new categorization of these tests allows the Illumigene platform to be available to all moderate-complexity labs in U.S. hospitals and clinics, allowing them to offer an accurate, rapid, simple molecular test for each of these pathogens.
Illumigene group A Streptococcus is a qualitative molecular test for the detection of group A strep pharyngitis. Clinical studies show that the test increased detection of positives by 53 percent over traditional culture in symptomatic patients.
Illumigene group B Streptococcus fully complies with CDC guidelines for the detection of GBS, and clinical studies have shown that broth enrichment, followed by testing with Illumigene group B Streptococcus, increased detection of true positives by 29 percent over traditional culture.
Meridian Bioscience, 513-271-3700